Video
Dr. Francesco Forconi on Questions That Remain Regarding Inhibiting the B-cell Receptor in CLL
Author(s):
Francesco Forconi, MD, associate professor of Hematology, University of Southampton, United Kingdom, discusses questions that remain regarding inhibiting the B-cell receptor (BCR) pathway for the treatment of patients with chronic lymphocytic leukemia (CLL).
Treatments such as idelalisib (Zydelig) and ibrutinib (Imbruvica), which inhibit the B-cell receptor (BCR) pathway, have shown success in the treatment of patients with CLL.
However, one question that remains is, why is the BCR variable, and can this variability be targeted therapeutically and more effectively, said Forconi.
While BCR-associated kinase inhibitors can be very effective therapeutic targets, they are not necessarily sufficient, he said.
There needs to be a better understanding of how B-cell signaling is influenced, what other pathways influence that, and how BCR-signaling inhibitors can be associated with other known genotoxic and chemotherapeutic agents.
